Skip to main content

Ind-Swift Limited (INDSWFTLTD.BO)

Bombay Stock Exchange (India) Healthcare Drug Manufacturers - Specialty & GenericView data quality →
52.6Fair

ValueMarkers Composite Index

Top 44%#25,210 of 44,714
Undervalued

98% below intrinsic value ($10)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.24
Low Risk
Altman
0.95
Distress
DCF Value
$10
Undervalued
ROIC
-1.5%
Low
P/E
0.3
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Ind-Swift Limited (INDSWFTLTD.BO) — VMCI valuation read

Ind-Swift Limited (INDSWFTLTD.BO) carries a VMCI composite of 53/100, 3 points above the Healthcare sector median of 50. Among mid-cap names, that gap places INDSWFTLTD.BO in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The INDSWFTLTD.BO insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads INDSWFTLTD.BO trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -2.1x leaves covenant headroom, the line to track on Ind-Swift Limited's next 10-Q.

INDSWFTLTD.BO fell 0.9% over the trailing 7 days, with a -20.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.